Keywords: expanded, use, sought, centocor, reopro, filed, supplemental
Expanded Use Sought For Centocor's ReoPro
Article | 24 February 1997
Centocor has filed two supplemental New Drug Applications for ReoPro(abciximab), its platelet glycoprotein IIb/IIIa antibody, in the USA.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
